Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine - Wikidata - wikimedia - TriplyDB

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

http://www.wikidata.org/entity/Q28255537

about

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Human papillomavirus vaccination: a case study in translational science Current status of human papillomavirus vaccines HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know Long-term efficacy and safety of human papillomavirus vaccination Safety of human papillomavirus vaccines: a review Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study Human papilloma virus in oral cancer The role of media and the Internet on vaccine adverse event reporting: a case study of human papillomavirus vaccination Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.Evaluating Social Media Networks in Medicines Safety Surveillance: Two Case Studies The prophylactic role for the human papillomavirus quadrivalent vaccine in males.HPV infection and cervical disease: a review.Safety of human papillomavirus vaccines: a review.Postural tachycardia syndrome following human papillomavirus vaccination.Deaths following vaccination: What does the evidence show?Postural Orthostatic Tachycardia With Chronic Fatigue After HPV Vaccination as Part of the "Autoimmune/Auto-inflammatory Syndrome Induced by Adjuvants": Case Report and Literature Review.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen.Behavioral correlates of HPV vaccine acceptability in the 2007 Health Information National Trends Survey (HINTS)EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome Gardasil® - The New HPV Vaccine: The Right Product, the Right Time? A Commentary Improving Human Papillomavirus (HPV) Vaccination in the Postpartum Setting.Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?Vaccines in the management of hypertension.Heterologous immunity: immunopathology, autoimmunity and protection during viral infections.Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome): clinical and immunological spectrum.Educational interventions to increase HPV vaccination acceptance: a systematic review.Asia oceania guidelines for the implementation of programs for cervical cancer prevention and control.HPV vaccine for cancer and wart prevention.Sub-acute toxicity study in female ICR mice following repetitive intramuscular injection of cervical cancer vaccines Using the North Dakota Immunization Information System to determine adolescent vaccination rates and uptake.The logic of surveillance guidelines: an analysis of vaccine adverse event reports from an ontological perspective How does public policy impact cervical screening and vaccination strategies?Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners.

P2860

Q24655328-9AA78F8F-0932-48E5-B8D2-6348FF046744 Q26799634-AE5F54E0-247B-4AFB-B604-F8F992532A5D Q26853556-2C790205-D9F2-4AE0-92FB-9518A77B79F8 Q26991640-7B02B399-3D19-4F44-A8A2-09213BAEC81F Q28072958-D2FA20AD-B702-4F90-A55E-61D6D8A1417B Q28081156-5E5BB423-7EF8-48CF-B2C8-33F2FB4F45F3 Q28082119-6A9D1054-3A84-4049-83ED-C15E11574CFC Q28088322-A1AFF343-7BF9-4735-9028-72BDE6E689AC Q28300023-CAC9957B-19F7-4613-9A07-2078EB2F7247 Q28357079-C832435D-70E8-4EE1-AE69-1E7E99C6F55A Q28658167-E893DF10-3C4A-4803-82E3-A7D0CCA2E1BA Q30622918-115F88B9-A9BD-4791-9BA2-1ACF349527D9 Q30665207-742F9080-B238-4367-8C3B-E2F5430B2AF9 Q33158795-D3289EAE-DF1F-412C-A2C3-B373FA4CBD20 Q33159907-DA61955A-0440-4825-A1F2-3FE03E9BF6D5 Q33162724-39ECF239-0FD4-47E3-96A1-E536FCCACD67 Q33163364-EF58C8FE-27AD-4996-B2F4-7FE5D727F080 Q33165769-EDC299B4-B3D2-4E58-B93A-54DFDAAFEEE3 Q33166316-67179D65-F679-453E-B32C-02A5F3819A47 Q33166996-2974ADC6-CE5B-4731-A361-1467F0C4707F Q33411345-2707DA9E-4123-449B-987D-1999CBBDBDC9 Q33594459-F17F804A-F117-4A58-8601-E513148E3F80 Q33645694-45BB226D-04F6-4C40-882C-36FFE29BE091 Q33731711-AC544C43-038E-4B4F-8D40-E8FF59F9E922 Q33874694-1B1F6110-BE7B-4B8E-A784-E166B312512D Q33905003-8E140EC1-6DCC-41A9-9424-BAAD2BF51A2C Q34029941-E7BA00C9-E589-405F-BC97-C3DC1767D042 Q34114402-71A1604A-BF5B-4E10-9B96-20518C5C9413 Q34159981-99C3E900-FE12-418E-B9AB-DFC1C321B1EF Q34271547-686EE152-0CB5-41AA-BFD0-BBE56237D7C7 Q34322342-9986A678-F001-40E0-9C9B-E1B5301F2641 Q34337165-8209F0C2-ED62-4A12-95D9-EF73912C4460 Q34846745-1FB6E697-26BF-4B0D-B848-175B662E1F08 Q34866621-3A9851F3-2759-4022-B8AB-B8BA5FC4866E Q34994797-B687EBA4-3CAE-4138-89FC-562715F19168 Q35038292-51626F7A-97C9-4842-9A8B-17831971D976 Q35040474-BAA9B0DA-085A-48BC-A5A7-34159813C874 Q35131475-393EDB46-0D9D-4197-801C-B4CA747C43C2 Q35646360-EE77048F-E0A2-44F0-8B29-8768C4BDEAD2 Q35792458-1785BA93-CC00-4710-83E0-678330FC86BA

P2860

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

http://www.wikidata.org/entity/Q28255537

description

2009 nî lūn-bûn

@nan

2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@ast

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@en

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@nl

type

label

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@ast

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@en

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@nl

prefLabel

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@ast

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@en

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@nl

P1433

Q28255537-82C7D694-9432-413E-97E9-465E386DC073

P1476

Q28255537-A379470D-B908-4425-AA3B-1F55B64D6F9E

P2093

Q28255537-03EB1807-4F0D-41E4-AF84-E75239F6A277

Q28255537-2B05CEF9-D2FA-4FF5-8F53-8BABF2B15AC7

Q28255537-4057CDC1-037A-490F-84CC-AAF8926D5283

Q28255537-40945CB3-A4BB-4ABB-8F33-00C40F85C8BE

Q28255537-6055EED1-2658-436F-93FD-AFFDF7EEBA0E

Q28255537-679B75FA-C047-4CB5-8868-A8E309F7AAA6

Q28255537-7AC22853-6B10-4D19-836B-F7FFCE74605F

Q28255537-93B5F12F-ED80-41B7-89E7-996C4320AC8D

Q28255537-AF0AFB69-8828-484D-82E9-B4DDEE1A4100

Q28255537-B56A8298-3E53-447A-B463-3D92573567FA

P304

Q28255537-4CC4E640-C401-4E98-B0E2-507BDA7D4595

P31

Q28255537-3209850C-CD4D-42BF-B7F4-9246C33AE765

P3181

Q28255537-EE6EA394-EE8F-4639-B8C5-1EB86BDD2CE7

P356

Q28255537-C2C267C1-4F72-4643-8823-6E2F5FF69DCA

P407

Q28255537-12B39421-B844-425A-82EF-8EC04D2D3EFA

P433

Q28255537-852296EE-4132-4789-A203-C489CB7D2A6E

P478

Q28255537-6F2431A9-247A-4DF0-B87C-FB838C8D85FF

P50

Q28255537-59C9CF96-21D5-40D3-A8DC-727003A32737

P577

Q28255537-37496323-FA73-4A9B-923D-E10C360EF3CB

P5875

Q28255537-4C5BBFF9-588D-42A8-B9B9-C28B5EA6DCD7

P698

Q28255537-41B54CC9-4450-434E-86A8-4ADD5DC85D9A

P3181

P356

P1433

Journal of the American Medical Association

P1476

Postlicensure safety surveilla ...... llomavirus recombinant vaccine

@en

P2093

Andrea Sutherland

http://www.w3.org/2001/XMLSchema#string

Barbara A Slade

http://www.w3.org/2001/XMLSchema#string

Claudia Vellozzi

http://www.w3.org/2001/XMLSchema#string

Emily Jane Woo

http://www.w3.org/2001/XMLSchema#string

Hector S Izurieta

http://www.w3.org/2001/XMLSchema#string

John Iskander

http://www.w3.org/2001/XMLSchema#string

Laura Leidel

http://www.w3.org/2001/XMLSchema#string

M Miles Braun

http://www.w3.org/2001/XMLSchema#string

Nancy Miller

http://www.w3.org/2001/XMLSchema#string

Robert Ball

http://www.w3.org/2001/XMLSchema#string

P304

750-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2065755

http://www.w3.org/2001/XMLSchema#string

P356

10.1001/JAMA.2009.1201

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

302

http://www.w3.org/2001/XMLSchema#string

P50

Lauri E Markowitz

P577

2009-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26751084

http://www.w3.org/2001/XMLSchema#string

P698

19690307

http://www.w3.org/2001/XMLSchema#string